Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03335722
Other study ID # R52173/RE001_
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 15, 2017
Est. completion date June 1, 2020

Study information

Verified date May 2022
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to test whether the application of transcranial direct current stimulation (tDCS) concurrent with fluency training results in improvements in speech fluency in adults with developmental stuttering, measured up to three months after the intervention.


Description:

Developmental stuttering affects 5% of children and persists to adulthood in about 1%. Changing the way speech is produced in adults who stutter is a particular challenge for speech and language therapy and there is a need for novel interventions. One such intervention involves the application of transcranial direct current stimulation (tDCS) alongside therapies aimed at improving speech fluency. tDCS influences brain activity by modulating neuronal plasticity through the application of weak electrical currents across the brain. Pairing tDCS with speech therapy has potential for producing larger or longer lasting effects and reducing time spent in therapy. The study will evaluate the potential of tDCS combined with speech fluency training to improve outcomes in people who stutter (PWS). PWS will have this training while receiving tDCS for five days (1 milliampere [mA] for 20 mins per day) in a double-blind randomized controlled trial. Outcomes will be measured in terms of changes to stuttering severity. An additional research questions is how changes in interactions between sensory and motor brain regions relate to changes in speech fluency in PWS. MRI will be used to measure brain structure and function and the vocal tract during speech production. Transcranial magnetic stimulation (TMS) will assess motor excitability before and after the training.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date June 1, 2020
Est. primary completion date June 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the study. - Diagnosed with developmental stuttering of mild-moderate or greater severity - Native speaker of English - Normal or corrected-to-normal vision - Normal hearing Exclusion Criteria: - Speech, language or communication disorder other than developmental stuttering. - Contraindication to brain stimulation (tDCS or TMS) - Contraindication to MRI - History of drug abuse - History of a neurological or psychiatric illness - Any previous neurosurgical procedures - Taking prescription or over-the-counter medication that may affect brain function (for example, anti-depressants) - Family history of epilepsy (first degree relative) - Severe claustrophobia (as they may be unable to tolerate scanner)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Metronome-timed speech
Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
Device:
Active tDCS
1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
Sham tDCS
Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.

Locations

Country Name City State
United Kingdom Department of Experimental Psychology, University of Oxford Oxford

Sponsors (1)

Lead Sponsor Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Premonitory Awareness in Stuttering Scale Change in total score on measure of anticipation of stuttering 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Other Change in Beck Anxiety Inventory Change in total score on the Beck Anxiety Inventory 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Other Change in Subjective rating of stuttering severity Change in self-rating on 9 point scale 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Other Change in Subjective rating of speech naturalness Change in self-rating on 9 point scale 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Other Change in Objective rating of stuttering severity Change in Researcher rating on 9 point scale 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Other Change in Objective rating of speech naturalness Change in Researcher rating on 9 point scale 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Primary Change in Stuttering Severity Instrument (SSI-4) Score The Stuttering Severity Instrument (SSI-4) is a standardised measure of stuttering severity comprised of 3 sub-scores (frequency, duration and physical concomitants) which are summed to give a total score. We will use change from baseline in total score (i.e. baseline subtracted) on the Stuttering Severity Instrument version 4 measured post intervention. The maximum total score of the SSI-4 is 56, which corresponds to the highest stuttering severity. Therefore, larger negative change scores represent better outcomes (larger reductions in stuttering severity). 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Secondary Change in percentage of disfluent syllables produced during conversation Change from baseline (i.e. baseline subtracted) in percentage of disfluent syllables produced during a two-minute conversation sample. Larger negative change scores represent better outcomes (larger reductions in frequency of disfluency). 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Secondary Change in percentage of disfluent syllables produced during reading Change from baseline (i.e. baseline subtracted) in percentage of disfluent syllables produced during a two-minute reading sample. Larger negative change scores represent better outcomes (larger reductions in frequency of disfluency). 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Secondary Change in Overall Assessment of the Speaker's Experience of Stuttering (OASES) score The Overall Assessment of the Speaker's Experience of Stuttering (OASES) is a standardised self-assessment to measure the effect of stuttering on a person's life, comprising of 4 sub-scores (general information about speech, your reactions to stuttering, communication in daily situations, quality of life). The total score (out of a possible 500) is divided by the number of items (out of a possible 100. Note that some items may not apply to all participants). This gives a total impact score between 1 and 5, with 5 representing the highest negative impact on person's life.
We will use change from baseline in total score (i.e. baseline subtracted) on the OASES total impact score, measured post intervention, as an outcome. Larger negative change scores represent better outcomes (larger reductions in negative impact of stuttering ).
6 weeks and 12 weeks after the end of the 5-day intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05908123 - Exploring the Nature, Assessment and Treatment of Stuttering N/A
Not yet recruiting NCT05437159 - Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech N/A
Terminated NCT03437512 - Non-invasive Brain Stimulation in Adults Who Stutter N/A
Recruiting NCT06181149 - Auditory Prediction and Error Evaluation in the Speech of Individuals Who Stutter N/A
Recruiting NCT05185726 - TreatPaCS = Treatment for Preschool Age Children Who Stutter N/A